Current Value
$1.411 Year Return
Current Value
$1.411 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTH | <0.01% | $1.58B | 0.07% |
YOLO | 0.01% | $24.75M | 1.12% |
USO | -0.04% | $982.22M | 0.6% |
LMBS | -0.05% | $5.06B | 0.64% |
GII | 0.05% | $544.21M | 0.4% |
DIAL | 0.08% | $363.60M | 0.29% |
FLBR | -0.08% | $208.61M | 0.19% |
SPIB | -0.08% | $9.34B | 0.04% |
CANE | 0.08% | $9.94M | 0.29% |
CORP | 0.10% | $1.39B | 0.23% |
BIL | 0.12% | $43.88B | 0.1356% |
HYDR | -0.16% | $32.57M | 0.5% |
STIP | -0.16% | $12.60B | 0.03% |
AGGH | -0.18% | $317.99M | 0.29% |
DFGR | -0.21% | $2.52B | 0.22% |
EWZS | -0.21% | $161.49M | 0.6% |
IGF | -0.23% | $7.24B | 0.42% |
OWNS | -0.25% | $127.67M | 0.3% |
UCON | 0.25% | $2.97B | 0.86% |
CNBS | -0.26% | $53.95M | 0.77% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IIPR | 39.04% | $1.58B | -47.15% | 13.32% |
CDRE | 30.20% | $1.40B | +4.88% | 1.06% |
SCHL | 29.36% | $497.18M | -45.55% | 4.25% |
NVO | 27.28% | $268.72B | -43.98% | 2.13% |
RXST | 26.02% | $577.45M | -75.45% | 0.00% |
LOPE | 24.53% | $5.25B | +34.37% | 0.00% |
MRSN | 24.39% | $45.76M | -82.26% | 0.00% |
RMBS | 24.39% | $6.24B | +2.02% | 0.00% |
THRY | 24.07% | $562.04M | -32.55% | 0.00% |
ODFL | 23.88% | $33.85B | -7.27% | 0.67% |
SAIA | 23.74% | $6.95B | -42.39% | 0.00% |
AMED | 23.50% | $3.19B | +5.82% | 0.00% |
KEX | 22.94% | $6.22B | -4.55% | 0.00% |
XPO | 22.88% | $14.19B | +16.95% | 0.00% |
GXO | 22.80% | $4.92B | -10.39% | 0.00% |
KRNY | 22.38% | $402.98M | +16.20% | 6.97% |
NFBK | 22.30% | $503.41M | +51.60% | 4.29% |
YMAB | 22.25% | $213.34M | -60.45% | 0.00% |
NPO | 21.88% | $3.96B | +29.88% | 0.64% |
ATRO | 21.84% | $1.23B | +89.20% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HE | -<0.01% | $1.81B | +7.26% | 0.00% |
BULL | -<0.01% | $4.80B | -6.40% | 0.00% |
MTN | -0.02% | $5.63B | -13.95% | 5.81% |
TRMD | 0.02% | $1.82B | -45.08% | 21.70% |
NVGS | 0.02% | $1.01B | -8.19% | 1.39% |
OKE | 0.02% | $52.31B | +7.23% | 4.84% |
RIVN | 0.02% | $15.38B | +23.35% | 0.00% |
SPRU | -0.03% | $32.80M | -44.07% | 0.00% |
XIFR | -0.03% | $828.15M | -68.48% | 20.55% |
PRMB | -0.03% | $11.15B | +36.93% | 1.28% |
FPI | 0.04% | $525.21M | +1.37% | 2.09% |
TCOM | -0.05% | $39.18B | +19.32% | 0.49% |
JKS | -0.05% | $976.41M | -17.49% | 0.00% |
LKQ | 0.06% | $9.84B | -5.39% | 3.13% |
COOP | -0.06% | $9.16B | +74.94% | 0.00% |
GORV | 0.06% | $27.46M | -92.14% | 0.00% |
NFG | -0.07% | $7.60B | +54.57% | 2.44% |
LPTX | -0.09% | $16.99M | -80.57% | 0.00% |
JKHY | -0.09% | $13.04B | +10.85% | 1.26% |
NFE | -0.10% | $751.25M | -87.57% | 3.67% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -13.01% | $104.89M | 0.59% |
CGSM | -12.80% | $690.97M | 0.25% |
IBMS | -11.37% | $80.26M | 0.18% |
FLIA | -10.87% | $675.48M | 0.25% |
UNG | -10.56% | $338.89M | 1.06% |
BTAL | -10.24% | $291.96M | 1.43% |
BSMW | -9.96% | $102.44M | 0.18% |
FMHI | -9.57% | $755.21M | 0.7% |
SHYD | -9.57% | $325.69M | 0.35% |
WIP | -9.33% | $375.60M | 0.5% |
CMBS | -9.23% | $440.96M | 0.25% |
PFFR | -9.19% | $93.18M | 0.45% |
TAXF | -9.01% | $489.92M | 0.29% |
SHM | -8.93% | $3.39B | 0.2% |
IBTM | -8.89% | $320.83M | 0.07% |
FLGV | -8.85% | $996.62M | 0.09% |
SCHQ | -8.81% | $792.73M | 0.03% |
TLT | -8.72% | $49.42B | 0.15% |
IBMP | -8.60% | $542.72M | 0.18% |
FEMB | -8.58% | $162.01M | 0.85% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TPIC | -20.45% | $52.54M | -75.84% | 0.00% |
CORT | -16.36% | $7.43B | +141.84% | 0.00% |
CLW | -16.08% | $447.52M | -45.73% | 0.00% |
WHWK | -15.13% | $92.33M | +15.98% | 0.00% |
AVO | -14.21% | $870.72M | +20.18% | 0.00% |
AMT | -14.19% | $100.56B | +9.02% | 3.86% |
LCID | -13.68% | $6.41B | -16.67% | 0.00% |
AQB | -12.16% | $3.14M | -53.66% | 0.00% |
SUI | -11.93% | $15.78B | +9.50% | 3.01% |
O | -11.41% | $52.05B | +8.00% | 5.50% |
K | -11.26% | $27.71B | +38.87% | 2.84% |
SJM | -11.21% | $10.19B | -14.21% | 4.49% |
VSTS | -11.06% | $770.93M | -50.00% | 2.36% |
VSTA | -10.98% | $344.07M | +37.94% | 0.00% |
AEP | -10.81% | $54.97B | +16.93% | 3.56% |
PARAA | -10.60% | $15.15B | +23.94% | 0.89% |
CHD | -10.26% | $23.91B | -9.85% | 1.19% |
BB | -10.03% | $2.44B | +74.36% | 0.00% |
MO | -9.88% | $100.75B | +34.95% | 6.89% |
BGS | -9.82% | $346.32M | -48.27% | 17.43% |
Yahoo
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and port
Yahoo
NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last
Finnhub
Galectin Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 9.63 million compared to USD 11.49 million...
Yahoo
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer patients in the belapectin treatment arms experienced worsening of liver stiffness as measured by FibroScan®, reinforcing the potential beneficial effect of belapectin in halting the progression of MASH cirrhosis. NORCROSS, Ga., May 12, 2025 (GLOBE
Finnhub
Galectin Therapeutics Corporate Overview May 2025 ...
Finnhub
Galectin Therapeutics announced that Data presentation included efficacy and biomarker analyses from the NAVIGATE trial . Belapectin 2 mg/kg demonstrated a statistically significant reduction in new...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SNSR | 19.45% | $224.52M | 0.68% |
IWC | 19.18% | $810.66M | 0.6% |
XSD | 18.77% | $1.25B | 0.35% |
VTWO | 18.35% | $12.36B | 0.07% |
IWM | 18.33% | $64.27B | 0.19% |
GSSC | 18.33% | $552.27M | 0.2% |
EES | 18.30% | $584.70M | 0.38% |
IWO | 18.22% | $11.29B | 0.24% |
XSVM | 18.17% | $567.15M | 0.37% |
ARKG | 18.15% | $974.51M | 0.75% |
SOXQ | 18.14% | $487.46M | 0.19% |
SOXX | 18.13% | $12.71B | 0.35% |
XME | 18.11% | $1.85B | 0.35% |
EWJ | 17.94% | $14.92B | 0.5% |
DFAS | 17.86% | $10.04B | 0.27% |
BBJP | 17.80% | $13.08B | 0.19% |
XTN | 17.79% | $179.13M | 0.35% |
IDMO | 17.79% | $969.82M | 0.25% |
FTXL | 17.76% | $264.80M | 0.6% |
AVUV | 17.69% | $15.87B | 0.25% |